LABVOLUTION Digital Edition | September 2021
Lab Infrastructures

Pathogens beware!

QIAGEN has set out to detect the 24 most common viral, bacterial and parasitic pathogens responsible for GI infections reliably, quickly and without breaking the bank. Its solution is the next-generation QIAstat-Dxâ panel for one-step, fully integrated molecular analysis.

28 Nov. 2018

The latest generation of the QIAstat-Dxâ panel for the one-step, fully integrated molecular analysis of GI syndromes is a multiplex gastrointestinal panel that QIAGEN has upgraded to now include comprehensive viral coverage. What’s more, a respiratory panel for QIAstat-Dx analyzes 21 viral and bacterial pathogens - including sub-types of influenza, coronaviruses, pneumonia and other targets - to differentiate the causes of acute respiratory tract infections.

Having already secured CE-IVD marking, together with the gastrointestinal and respiratory panels, the QIAstat-Dx system was recently successfully registered and launched in Australia. Plans are currently underway to submit QIAstat-Dx and both panels for U.S. regulatory approval, which is expected to be granted in 2019. In the same year, QIAGEN aims to launch a QIAstat-Dx multiplex test for meningitis, once again with CE-IVD marking. The company is also working on an extensive range of assays for syndromic testing in oncology and other areas of therapy.

"Hospitals, laboratories and clinics are embracing QIAstat-Dx as an easy-to-use, next-generation solution for reliably diagnosing complex syndromes," says Thierry Bernard, QIAGEN’'s Senior Vice President for Molecular Diagnostics. "With less than one minute of hands-on time and results in about an hour, a clinic assistant or technician can run multiple samples and gain reliable, highly sensitive molecular insights that differentiate the causes of respiratory or gastrointestinal syndromes. QIAstat-Dx's simplicity brings the power of real-time PCR (polymerase chain reaction) technology close to the patient. All the user has to do is insert a sample cartridge, then they can walk away. The instrument automatically handles all of the steps of multiplex molecular analysis - enabling the clinician to make informed treatment decisions."

QIAstat-Dx is designed to be deployed in clinical environments close to the patient so as to avoid delays caused by sending samples to a central laboratory. Its user-friendly cartridges are processed in a scalable, proprietary analyzer. Using a touchscreen with simple step-by-step instructions, this device can be configured for up to eight modules, separately analyzing the cartridges according to predefined assay protocols.

QIAGEN GmbH - Germany (40724 Hilden, Germany)

If you have any problems with the view then go to.